Clairity becomes the first FDA-authorized AI platform for breast cancer prediction – historic milestone for women’s health
Business Announcement
Updates every hour. Last Updated: 18-Jun-2025 14:10 ET (18-Jun-2025 18:10 GMT/UTC)
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.
In a new multi-center study led by Boston University Chobanian & Avedisian School of Medicine, researchers have found that aggressive surgery in patients with advanced gallbladder cancer (T3/T4) can lead to high complication and mortality rates, especially in those in the T4 patients that invade adjacents organs of the disease.
A new study by researchers from Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, has found that more than 110,000 firearm suicides could potentially have been prevented (from 2010-2019) had each state implemented the most impactful firearm related law in that state, specifically including child access prevention laws and concealed carry permitting policies.
A novel study reveals a significantly higher concentration of recreational (nonmedical) cannabis retailers in socioeconomically disadvantaged areas and neighborhoods with greater proportions of populations of color across 18 US states in which cannabis use is legal for adults. The study, appearing in the American Journal of Preventive Medicine, published by Elsevier, offers critical insights for policymakers and public health officials, underscoring the need for strategies to ensure equitable distribution of cannabis retailers.